Click to refer colleagues and get 30% off

Newsroom

Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials
Press Release
Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials
Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to advance Genetic Immunity's innovative HIV vaccine into a late-stage clinical trial. Read More ››
VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation
Press Release
VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation
VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration will focus on gene vector and mRNA bioprocess solutions and services, accelerating the development and clinical translation of innovative biopharmaceutical projects. Read More ››
VectorBuilder Wins BioIndustrial Innovation of the Year Award
Press Release
VectorBuilder Wins BioIndustrial Innovation of the Year Award
VectorBuilder, a global leader in gene delivery solutions, is excited to announce that it’s received the BioIndustrial Innovation of the Year award by the BioTech Breakthrough Awards. The recognition underscores VectorBuilder’s significant contributions to gene delivery technology through its Vector Design Studio, which has revolutionized the way researchers worldwide create and order custom gene delivery vectors. Read More ››
VectorBuilder’s Chief Scientist Dr. Bruce Lahn Named to Forbes China’s Top 100 Most Influential Chinese
Press Release
VectorBuilder’s Chief Scientist Dr. Bruce Lahn Named to Forbes China’s Top 100 Most Influential Chinese
VectorBuilder, a global leader in gene delivery solutions, proudly announces that its chief scientist, Dr. Bruce Lahn, has been recognized on the 2024 Forbes China 100 Most Influential Chinese list. This distinguished annual selection honors 100 prominent Chinese figures shaping business, culture, and philanthropy globally, with past recipients including NVIDIA's Jenson Huang. Dr. Lahn was chosen for his pivotal contributions to advancing life sciences worldwide. Read More ››
VectorBuilder’s Chief Scientist, Dr. Bruce Lahn Named to the 2024 PharmaVoice 100
Press Release
VectorBuilder’s Chief Scientist, Dr. Bruce Lahn Named to the 2024 PharmaVoice 100
VectorBuilder, a global leader in gene delivery solutions, announced today that its Chief Scientist, Dr. Bruce Lahn, has been honored as a PharmaVoice 100 winner. Read More ››
Groundbreaking Study Solves Mystery of Multicellularity
Press Release
Groundbreaking Study Solves Mystery of Multicellularity
A team of researchers from multiple institutions including the University of Chicago and VectorBuilder, has made a significant breakthrough in the understanding of lineage restriction. Read More ››
VectorBuilder supported Lantu Biopharma's gene therapy drug for Menkes Disease to receive FDA Orphan Drug Designation
Press Release
VectorBuilder supported Lantu Biopharma's gene therapy drug for Menkes Disease to receive FDA Orphan Drug Designation
VectorBuilder Inc., a global leader in gene delivery technologies, announced that its partner, Lantu Biopharma, has received Orphan Drug Designation (ODD) from the FDA for LTGT06, a gene therapy targeting Menkes Disease. VectorBuilder provided comprehensive CRO and CDMO services for the development of this therapy. Read More ››
High Prevalence of Errors Found in Lab-Made Plasmids Globally: Study Reveals Critical Quality Control Issues
Press Release
High Prevalence of Errors Found in Lab-Made Plasmids Globally: Study Reveals Critical Quality Control Issues
A new study conducted by VectorBuilder, a global leader in plasmid design and gene delivery solutions, has unveiled alarming rates of errors in lab-made plasmids worldwide, which reveals that nearly 50% of plasmids used in life sciences research and therapeutic development contain significant design and sequence errors that could severely impact their functionality. Read More ››
VectorBuilder Included in Global Unicorn Index by Hurun Research Institute
Press Release
VectorBuilder Included in Global Unicorn Index by Hurun Research Institute
On April 9, the Hurun Research Institute released the Global Unicorn Index 2024 in Guangzhou, a ranking of the world’s startups founded in the 2000s, worth at least a billion dollars and not yet listed on a public exchange. Read More ››
Build a Better Future with VectorBuilder
Press Release
Build a Better Future with VectorBuilder
This year marks VectorBuilder’s 10-year anniversary. We have come a long way and accomplished a lot, for which we should all be very proud. But we have an even longer way to go, and even greater things to accomplish in the years to come. So, let me take this opportunity to lay out the vision of VectorBuilder’s future, which I call the “VectorBuilder Dream”. Read More ››
Minaris Regenerative Medicine and VectorBuilder Collaborate to Accelerate Therapeutic Breakthroughs
Press Release
Minaris Regenerative Medicine and VectorBuilder Collaborate to Accelerate Therapeutic Breakthroughs
VectorBuilder, a global leader in gene delivery technologies, is thrilled to announce its partnership with Minaris Regenerative Medicine (Minaris), a leading contract development and manufacturing organization (CDMO) focusing on cell and gene therapies (CGT). This strategic collaboration aims to leverage VectorBuilder’s integrative know-how on GMP vector manufacturing and Minaris’s extensive CGT manufacturing track records to further advance comprehensive solutions for customers in need of cutting-edge CGT development. Read More ››
VectorBuilder Leverages Danaher Solutions to Advance Gene Delivery Technologies
Press Release
VectorBuilder Leverages Danaher Solutions to Advance Gene Delivery Technologies
VectorBuilder, a global leader in gene delivery technologies, is pleased to announce it will utilize strategic new capabilities from global life sciences and diagnostics innovator Danaher Corporation to advance scientific research and clinical applications in the gene delivery industry to improve human health. Read More ››
Cambodian Deputy Prime Minister SUN Chanthol Visits VectorBuilder to Explore the Collaboration in the Medical and Health Sector
Press Release
Cambodian Deputy Prime Minister SUN Chanthol Visits VectorBuilder to Explore the Collaboration in the Medical and Health Sector
Cambodian Deputy Prime Minister and First Vice Chairman of Council for the Development of Cambodia (CDC), SUN Chanthol, along with senior government officials from entities including the Foreign Trade Bank and the Investment Committee, conducted an official visit to VectorBuilder’s R&D and manufacturing base in Guangzhou, China. Read More ››
VectorBuilder Japan Launches Gene Therapy Pilot Program for Rare Disease Menkes in Japan
Press Release
VectorBuilder Japan Launches Gene Therapy Pilot Program for Rare Disease Menkes in Japan
VectorBuilder Japan is thrilled to announce the inclusion of its collaborative initiative, the "Menkes Rare Pediatric Disease Clinical Research Pilot Program," in the Japan External Trade Organization's (JETRO) subsidy program for foreign direct investment. In partnership with Lantu Biopharma, Teikyo University, and Teikyo Heisei University, VectorBuilder brings its extensive expertise in rapid gene therapy development, production, and quality control to further explore gene therapy technologies for treating Menkes disease. Read More ››
Recent Cash Injection Boosts VectorBuilder to Unicorn Status
Press Release
Recent Cash Injection Boosts VectorBuilder to Unicorn Status
Gene delivery technologies are turning into the next big-ticket item globally, as the most recent investment received by VectorBuilder Inc., a global leader in this field, from multiple venture capital firms has shown. The latest cash injection builds on the $57 million Series C funding completed in November last year, which brings the total amount raised to date to just over $76 million and propels the organization to unicorn status with over $1 billion valuation. Read More ››
Please let us know what you would like to hear from us about the latest technologies or discoveries by leaving feedback or contacting us.
Design My Vector Request Design Support